Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 68.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,402 shares of the company’s stock after purchasing an additional 13,215 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Teva Pharmaceutical Industries were worth $584,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC increased its stake in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after acquiring an additional 805 shares during the last quarter. Signaturefd LLC grew its position in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the last quarter. QRG Capital Management Inc. grew its stake in Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock worth $2,355,000 after buying an additional 1,191 shares during the last quarter. United Services Automobile Association grew its position in Teva Pharmaceutical Industries by 3.1% during the 2nd quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after purchasing an additional 1,249 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after buying an additional 1,741 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.3 %

NYSE TEVA opened at $17.03 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market capitalization of $19.29 billion, a PE ratio of -19.76, a price-to-earnings-growth ratio of 1.28 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 1-year low of $9.27 and a 1-year high of $19.31. The firm’s fifty day simple moving average is $17.74 and its 200-day simple moving average is $17.30.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Barclays raised their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.